[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"monocyte\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:monocyte":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100621576","macrophagemonocyte-driven-inflammation-and-anesthetic-sensitivity-in-aging-100621576",false,"NCT07372417","Macrophage\u002FMonocyte Driven Inflammation and Anesthetic Sensitivity in Aging","Role of Macrophage\u002FMonocyte Mediated Inflammatory Response in Diminished Anesthetic Requirements During Aging","MACRO-AGE","Inclusion Criteria:\n\n* Age between 18-30 years or over 60 years old\n* Scheduled for abdominal surgery\n* General anesthesia planned with or without spinal anesthesia\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Chemotherapy or systemic corticosteroid use within the past 2 weeks.\n* Pregnancy.\n* Active sepsis or systemic infection.\n* Emergency surgery.\n* Requirement of ketamine or dexmedetomidine during the first hour of anesthesia.\n* History or diagnosis of: stroke with persistent neurological deficit, dementia, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, central nervous system autoimmune disorders, systemic autoimmune diseases, or infectious diseases of the central nervous system.\n* Current treatment with immunomodulatory medications.\n* Psychiatric disorders with psychotic features.\n* Use of psychoactive or psychotropic recreational drugs within the week prior to surgery.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","1 Day","OBSERVATIONAL","The goal of this observational study is to determine whether macrophage\u002Fmonocyte mediated inflammatory signaling contributes to reduced anesthetic requirements in older adults undergoing major abdominal surgery. The main questions it aims to answer are:\n\n* Is there a difference in anesthetic dosing requirements (minimum effective dose) between young and older patients undergoing major abdominal surgery?\n* How do electroencephalographic (EEG) signatures under anesthesia correlate with age and systemic inflammatory markers?\n* Is there an association between age, levels of circulating inflammatory cytokines, and monocyte\u002Fmacrophage phenotypes with anesthetic requirements?\n\nIf there is a comparison group: Researchers will compare older adult patients undergoing major abdominal surgery to younger adult patients undergoing major abdominal surgery to see if macrophage\u002Fmonocyte-mediated inflammatory signaling influences anesthetic sensitivity and the risk of postoperative neurocognitive complications in the older population.\n\nParticipants will:\n\n* Receive general anesthesia for major abdominal surgery, with continuous recording of anesthetic dose requirements.\n* Undergo electroencephalographic (EEG) monitoring during the anesthetic period.\n* Provide blood samples for the measurement of circulating inflammatory cytokines and the assessment of monocyte phenotypes.\n* Provide peritoneal tissue samples (collected during surgery) to evaluate tissue macrophage populations.\n* Provide cerebrospinal fluid (CSF) samples to assess biomarkers of blood-brain barrier permeability.",[26,27,28,29,30,31,32,33],"Aging","Inflammation","Blood-Brain Barrier Permeability","Anesthesia Brain Monitor","Anesthesia Depth Monitoring","Inflammation Biomarkers","Inflammaging","Monocyte",[26,27,35,36,37,38,39,40,41],"General Anesthesia","Anesthetic Sensitivity","Cytokines","Alpha Oscillations","Blood Brain Barrier","Monocyte phenotype","macrophage phenotype","NOT_YET_RECRUITING","2026-01-19",{"date":45,"type":46},"2026-01-28","ACTUAL",{"date":48,"type":21},"2026-01-25",{"date":50,"type":21},"2027-06-15",{"name":52,"class":53},"University of Chile","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":54},"100581671","impact-of-vascular-calcification-and-casr-expression-by-monocytes-in-septic-shock-100581671","NCT06853340","Impact of Vascular Calcification and CASR Expression by Monocytes in Septic Shock","CASRCHOC","Inclusion Criteria:\n\n* Male or female patients over the age of 18,\n* patients who have not participated in a study evaluating an investigational drug in the 30 days preceding the samples,\n* intensive care patients in a state of septic shock within the first 24 hours of the introduction of pressor amines,\n* French resident year-round,\n* lactate \\> 2mmol\u002FL,\n* patients with social security coverage.\n\nExclusion Criteria:\n\n* Patients in hemorrhagic shock,\n* history of parathyroidectomy, patient with hypersecretion of PTHrp,\n* sarcoidosis,\n* genetic disturbance of CaSR including familial hypocalciuric hypercalcaemia,\n* current immunosuppressant treatment (anticalcineurin, mTOR inhibitor, methotrexate, high-dose corticosteroids excluding hydrocortisone and fludrocortisone),\n* chronic myelomonocytic leukemia,\n* patients with febrile neutropenia,\n* patients with acquired or constitutional immune system,\n* pregnant or breastfeeding patient,\n* patients under curators, guardianship or safeguard of justice.",true,{"count":64,"type":21},66,"INTERVENTIONAL",[67],"NA","In septic shock, bacterial LPS is able to activate the CaSR of cardiomyocytes inducing their apoptosis in vitro. CaSR activation in monocytes is responsible for activation of the NLRP3 inflammasome and macropinocytosis. In front of this immune axis, a variation in the monocyte expression of the CaSR is expected in the state of shock. This is already observed in other pathologies such as renal failure or in animal models of severe burns. If this is considered as an overall reflection of CaSR expression in the body, it would be consistent with the phosphocalcic disturbances associated with septic shock. The phosphocalcic balance is often modified, and not treated during the acute episode, with in particular hypocalcaemia which could be consecutive to a hyperactivation or overexpression of the CaSR. This study proposes to explore for the first time the expression of monocytic CaSR in patients in a state of shock, with possible therapeutic perspectives by the existence of calcimimetics and calcilytics. In this study, the investigators propose to explore the CasR and its implication in septic shock in a three - part protocol : measurement by flow cytometry of monocyte expression of CASR (primary objective) and CD33, CD14, CD163, CD16 and HLA-DR), survey of clinical and biological parameters in patients with septic shock and healthy volunteers and acquisition of calcium score in patients with septic shock.",[70,71,72,27,33],"Septic Shock","Calcium Sensing Receptor","Calcium Phosphate Disorders",[74,71,75,27,33],"Septic shock","Calcium Phosphate disorders","RECRUITING","2025-04-24",{"date":79,"type":46},"2025-04-25",{"date":81,"type":46},"2025-02-24",{"date":83,"type":21},"2027-02",{"name":85,"class":53},"Centre Hospitalier Universitaire, Amiens"]